The global Human Recombinant Insulin Market is segmented based on product type, brand, distribution channel, and region as follows:
- Product Type (Revenue, USD Billion; 2022–2030)
- Rapid-Acting Human Insulin
- Short-Acting Human Insulin
- Intermediate-Acting Human Insulin
- Long-Acting Human Insulin
- Premixed Human Insulin
- Brand Product (Revenue, USD Billion; 2022–2030)
- Humalog
- Novolog
- Apidra
- Humulin R
- Novolin R
- Humulin N
- Novolin N
- Levemir
- Lantus
- Humalog Mix
- Novolog Mix
- Others
- Distribution Channel (Revenue, USD Billion; 2022–2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region (Revenue, USD Billion; 2022–2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
- North America
Frequently Asked Questions
The current market size of the Human Recombinant Insulin industry is approximately US$ 37.9 billion.
Factors such as the increasing prevalence of diabetes and advancements in insulin delivery technologies are contributing significantly to the growth of the Human Recombinant Insulin market.
Key factors hampering the growth of the Human Recombinant Insulin Market include pricing pressures and competition from biosimilar insulin products.
The leading component segment in the Human Recombinant Insulin Market is the Insulin Analog segment.
Major players operating in the Human Recombinant Insulin Market include Novo Nordisk, Eli Lilly, Biocon Ltd., and Sanofi.
The CAGR of the Human Recombinant Insulin Market is projected to be around 7.8%, with a market size expected to reach US$ 64 billion by 2030